KEGG   DRUG: TrastuzumabHelp
Entry
D03257                      Drug                                   

Name
Trastuzumab (INN);
Trastuzumab (genetical recombination) (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN);
Herceptin (TN)
Product
Sequence
(Heavy chain) EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA
PGKGLEWVAR IYPTNGYTRY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG
GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS
WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP
KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW
YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS
KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG
(Disulfide bridge: 22-96; 147-203; 264-324; 370-428, Dimer: 229; 232)
(Light chain) DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP
GKAPKLLIYS ASFLYSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: 23-88; 134-194; H223-L214, Dimer)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01XC03
Product: D03257<JP/US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody
  Disease
Breast cancer (HER2 overexpressing) [DS:H00031]
Gastric cancer (HER2 overexpressing) [DS:H00018]
Comment
Monoclonal antibody
Target
ERBB2 (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
  Network
N10009  Tyrosine kinase inhibitor to HER2 overexpression/amplification
  Pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
hsa05226  Gastric cancer
Structure map
map07045  Antineoplastics - protein kinases inhibitors
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC03 Trastuzumab
      D03257  Trastuzumab (INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D03257  Trastuzumab (INN); Trastuzumab (genetical recombination) (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN); Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN)
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2 (HER2, CD340) [HSA_VAR:2064v1]
     D03257  Trastuzumab (INN) <JP/US>
Antineoplastics [br08340.html]
 D03257
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03257
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D03257
Pharmacogenomic biomarkers [br08341.html]
 Companion diagnostics
  D03257
BRITE hierarchy
Other DBs
CAS: 180288-69-1
PubChem: 17397410
DrugBank: DB00072
NIKKAJI: J2.044.149F
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system